8-K current report · filed Sep 25, 2026

CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) 8-K Current Report: September 25, 2026

Item 5.02Item EX-99.1CLOV overview

Short answer

CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) filed an 8-K current report with the SEC on September 25, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1). Two vacancies filled, expanding Clover’s Board to nine directors.

CLOVER HEALTH INVESTMENTS, CORP. /DE 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Two vacancies filled, expanding Clover’s Board to nine directors
  • Senator Torricelli joins Audit Committee, adding healthcare-services and governance experience
  • Dr. Miller joins Clinical Committee, adding Medicare policy, regulation and health-plan expertise
  • Each director receives prorated retainers plus a prorated $200,000 RSU award for 2026
  • Appointments strengthen oversight during regulatory and clinical execution priorities

Item EX-99.1 · Exhibit EX-99.1

  • Two directors appointed effective immediately, filling vacancies and expanding the Board to nine directors
  • Former Senator Torricelli joins the Audit Committee, adding federal healthcare policy and business oversight experience
  • Dr. Brian Miller joins the Clinical Committee, bringing Medicare payment, regulatory, and frontline physician expertise
  • Appointments strengthen oversight of Clover’s Medicare Advantage strategy, clinical technology, and policy exposure
  • No transaction or financial obligation disclosed; investor impact centers on governance and execution credibility

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other CLOVER HEALTH INVESTMENTS, CORP. /DE 8-K filings

Get the next CLOV 8-K as it lands

Follow CLOV for push alerts, or ask the research agent what this filing means.